GlassScriptPhysician profile
Elizabeth Nadal
NPI 1730508946
$4,586.04
in general payments reported to CMS, 2019-2025
27 companies · $1,258 in 2025
The $1,258 reported for 2025 was more than what 92% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $147 · 2021: $375 · 2022: $917 · 2023: $1,100 · 2024: $640 · 2025: $1,258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,828 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,827.97 |
| Education | $169.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $772.55 | 2019-2023 | |
| Exeltis, USA INC. | $723.10 | 2019-2025 | Slynd, Tyblume |
| Mayne Pharma Commercial LLC | $700.05 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $287.36 | 2023-2025 | Myfembree, Gemtesa |
| Merck Sharp & Dohme LLC | $225.84 | 2019-2024 | Gardasil 9, Gardasil |
| Astellas Pharma US INC | $188.77 | 2023-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $185.19 | 2023-2025 | |
| Millicent US INC | $181.48 | 2025 | Femlyv, Intrarosa |
| Therapeuticsmd, INC. | $174.75 | 2021-2022 | |
| Exact Sciences Corporation | $170.54 | 2023-2025 | Cologuard Collection Kit |
| Biogen, INC. | $168.60 | 2025 | Zurzuvae |
| Myovant Sciences INC. | $133.07 | 2021-2022 | |
| Organon LLC | $118.36 | 2021-2025 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $118.17 | 2022-2025 | |
| Scynexis, INC. | $84.81 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agile Therapeutics, INC. | $80.11 | 2021-2022 | |
| Medicem INC. | $36.08 | 2020-2022 | |
| Allergan, INC. | $35.59 | 2019-2020 | |
| Shield Therapeutics INC | $32.82 | 2023-2025 | Accrufer |
| Avion Pharmaceuticals | $32.76 | 2021 | |
| Novo Nordisk INC | $25.28 | 2025 | Wegovy |
| Aspira Women'S Health INC | $23.73 | 2025 | Ova1 |
| Coopersurgical, INC. | $23.64 | 2024 | Paragard T 380a |
| Duchesnay USA Incorporated | $19.03 | 2019 | |
| Amag Pharmaceuticals, INC. | $16.11 | 2019 | |
| Evofem Biosciences, INC. | $15.46 | 2022 | |
| Covidien LP | $12.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Nadal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.